Galaxy Diagnostics secures investment from Bay Area Lyme Ventures for tick-borne disease testing
What's the deal? Bay Area Lyme Ventures, an impact investment fund created by Bay Area Lyme FoundationDealroom has a profile for this one. Try Dealroom →, has made a strategic investment in Galaxy DiagnosticsDealroom has a profile for this one. Try Dealroom →, a Durham, North Carolina-based company specialising in advanced vector-borne disease testing. The specific investment amount was not disclosed.
Galaxy Diagnostics was founded by leaders in vector-borne disease research to detect stealth pathogens that conventional testing often misses. Its portfolio includes molecular testing, antigen detection technologies, and diagnostic collaborations that translate lab discoveries into clinical tools.
Why now? Reported tick-borne disease cases have more than doubled in the US over the past two decades, creating urgent demand for better diagnostics. Bay Area Lyme Ventures launched in 2025 as the first venture philanthropy fund dedicated to Lyme disease solutions, targeting companies with promising diagnostics and therapeutics nearing commercialisation.
Earlier in 2026, Galaxy announced a licensing agreement with Virginia TechDealroom has a profile for this one. Try Dealroom → to advance Borrelia peptidoglycan antigen detection research — work partly funded by Bay Area Lyme Foundation — into its diagnostic pipeline. The investment effectively closes a loop: the foundation funded the underlying science, and its venture arm now backs the company bringing it to patients.
"Bay Area Lyme has funded much of the foundational research that Galaxy is now bringing to patients — the investment in Galaxy reflects their commitment to seeing those innovations through to the clinic," said Nicole Bell, chief executive officer of Galaxy Diagnostics.
What could go wrong? Diagnostics for complex tick-borne diseases remain scientifically challenging, and translating lab breakthroughs into reliable, widely accessible clinical tools is notoriously difficult. The venture philanthropy model — sitting between pure grant-making and traditional venture capital — is still relatively untested in this space.
The signal: Galaxy Diagnostics, classified as an early growth-stage company specialising in bartonella detection, sits at the intersection of two emerging trends: the rise of venture philanthropy in life sciences and growing investor attention toward infectious disease diagnostics that conventional testing overlooks. Bay Area Lyme Ventures' bet here suggests that disease-focused foundations are increasingly willing to deploy capital like traditional VCs to close the gap between funded research and commercialised products — a model that, if validated, could reshape how underfunded disease areas attract investment.
Read more: GlobeNewswire
